RXRX
Market cap | $1.67 Billion |
---|---|
Enterprise Value | $1.30 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-1.69 |
Beta | 0.98 |
Outstanding Shares | 402,771,972 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -2.93 |
---|---|
PEG | -2.41 |
Price to Sales | - |
Price to Book Ratio | 2.46 |
Enterprise Value to Revenue | 21.8 |
Enterprise Value to EBIT | -2.29 |
Enterprise Value to Net Income | -3 |
Total Debt to Enterprise | 0.1 |
Debt to Equity | 0.14 |
No data
No data
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patient...